Songyun Ouyang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Songyun Ouyang has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Liping Dai
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
19 shared publications Yifei Fang
Department of Respiratory and Sleep Medicine in the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
9 shared publications- Aichen Liu
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications Chunling Zhao
Department of Respiratory and Sleep Medicine in the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
8 shared publications- Fengqi Chen
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China
8 shared publications - Hanke Ma
Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers Zhengzhou University Zhengzhou China
8 shared publications
Latest Publications
- Open Access
- 25 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Circulating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea
While polysomnography (PSG) is the gold standard for diagnosing obstructive sleep apnea (OSA), its limited availability means that many patients remain undiagnosed. This study seeks to evaluate whether CHI3L1-Ab could serve as a diagnostic biomarker for OSA. A total of 366 individuals, including 333 OSA patients and 33 healthy controls, were recruited for this study, all of whom underwent polysomnography. Enzyme-linked immunosorbent assay (ELISA) was used to measure CHI3L1-Ab levels, and clinical factors were analyzed to assess their relationship with CHI3L1-Ab expression. OSA patients exhibited significantly higher CHI3L1-Ab levels compared to healthy controls (P < 0.05), with an area under the curve (AUC) of 0.721. Subgroup analysis revealed the highest AUC of 0.735 (95% CI 0.637–0.832) in patients with severe OSA. Logistic regression analysis, which incorporated age, BMI and CHI3L1-Ab levels, demonstrated strong predictive performance with an AUC of 0.846 (95% CI 0.815–0.942). The corresponding nomogram allowed individualized risk estimation based on these predictors. The combination of CHI3L1-Ab levels, age and BMI demonstrated strong predictive accuracy in distinguishing OSA from healthy individuals. These findings also suggest that elevated CHI3L1-Ab levels could serve as an independent diagnostic biomarker for OSA.
- 25 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessCirculating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea
While polysomnography (PSG) is the gold standard for diagnosing obstructive sleep apnea (OSA), its limited availability means that many patients remain undiagnosed. This study seeks to evaluate whether CHI3L1-Ab could serve as a diagnostic biomarker for OSA. A total of 366 individuals, including 333 OSA patients and 33 healthy controls, were recruited for this study, all of whom underwent polysomnography. Enzyme-linked immunosorbent assay (ELISA) was used to measure CHI3L1-Ab levels, and clinical factors were analyzed to assess their relationship with CHI3L1-Ab expression. OSA patients exhibited significantly higher CHI3L1-Ab levels compared to healthy controls (P < 0.05), with an area under the curve (AUC) of 0.721. Subgroup analysis revealed the highest AUC of 0.735 (95% CI 0.637–0.832) in patients with severe OSA. Logistic regression analysis, which incorporated age, BMI and CHI3L1-Ab levels, demonstrated strong predictive performance with an AUC of 0.846 (95% CI 0.815–0.942). The corresponding nomogram allowed individualized risk estimation based on these predictors. The combination of CHI3L1-Ab levels, age and BMI demonstrated strong predictive accuracy in distinguishing OSA from healthy individuals. These findings also suggest that elevated CHI3L1-Ab levels could serve as an independent diagnostic biomarker for OSA.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S3 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus BPN
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S3 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus BPN
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S1 shows the protein expression level of FDX1 in A549 and PC-9 cells by western blotting analysis.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S1 shows the protein expression level of FDX1 in A549 and PC-9 cells by western blotting analysis.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S2 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus NC.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S2 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups of NSCLC versus NC.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S4 shows the mRNA expression level of FDX1 in LUAD and LUSC patients based on GEPIA database.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Figure S4 shows the mRNA expression level of FDX1 in LUAD and LUSC patients based on GEPIA database.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S1 shows the characterization of all participants.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S1 shows the characterization of all participants.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S2 shows the combination analysis of anti–FDX1 autoantibody and CEA to distinguish NSCLC.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Supplementary Table S2 shows the combination analysis of anti–FDX1 autoantibody and CEA to distinguish NSCLC.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Background:Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC).Methods:A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.Results:Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively.Conclusions:Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.Impact:These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
Background:Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non–small cell lung cancer (NSCLC).Methods:A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.Results:Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772–0.839) and 0.627 (0.584–0.670), respectively.Conclusions:Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.Impact:These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.
- Open Access
- 20 December 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-16
ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target
Glycolysis plays a major role in progression of idiopathic pulmonary fibrosis (IPF). Here, we aim to explore the predictive signature based on glycolysis-related genes for predicting the prognosis and identified a potential therapeutic target for IPF. Gene expression data of bronchoalveolar lavage (BAL) cells and clinical information were downloaded from the Gene Expression Omnibus database. Bioinformatic analysis was then performed to identify differentially expressed genes (DEGs). Lasso multivariate cox analysis and multivariate Cox regression were used to establish a gene signature. The prediction model was evaluated using the time-dependent receiver operating characteristic (ROC) curve and validated using an external independent dataset. The expression of these key genes in cellular level analyzed from Single Cell Expression Atlas. Cell Counting Kit-8 assay, immunofluorescence, wound healing and plasmid transfection were performed. A total of 4 gene (ANGPTL4, ME2, TPBG and IER3), which were associated with the prognosis of IPF patients, were selected to establish our signature. The prediction model was an independent prognostic indicator for IPF patients. ANGPTL4 was significantly upregulated in pleural mesothelial cells (PMCs). In vitro assay showed that ANGPTL4 promoted PMCs proliferation and migration. Knockdown of ANGPTL4 can inhibit mesothelial-mesenchymal transition by suppressed glycolysis-associated gene, such as PGM1, GPI, PGK1, LDHA, ALDOA, ENO1 and TPI1. Our research established a glycolysis-associated gene signature that holds potential to assist clinicians in the personalized management of IPF. Furthermore, we identified that ANGPTL4 mediates mesothelial-mesenchymal transition, suggesting its viability as a therapeutic target for IPF treatment.
- 20 December 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-16
Open AccessANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target
Glycolysis plays a major role in progression of idiopathic pulmonary fibrosis (IPF). Here, we aim to explore the predictive signature based on glycolysis-related genes for predicting the prognosis and identified a potential therapeutic target for IPF. Gene expression data of bronchoalveolar lavage (BAL) cells and clinical information were downloaded from the Gene Expression Omnibus database. Bioinformatic analysis was then performed to identify differentially expressed genes (DEGs). Lasso multivariate cox analysis and multivariate Cox regression were used to establish a gene signature. The prediction model was evaluated using the time-dependent receiver operating characteristic (ROC) curve and validated using an external independent dataset. The expression of these key genes in cellular level analyzed from Single Cell Expression Atlas. Cell Counting Kit-8 assay, immunofluorescence, wound healing and plasmid transfection were performed. A total of 4 gene (ANGPTL4, ME2, TPBG and IER3), which were associated with the prognosis of IPF patients, were selected to establish our signature. The prediction model was an independent prognostic indicator for IPF patients. ANGPTL4 was significantly upregulated in pleural mesothelial cells (PMCs). In vitro assay showed that ANGPTL4 promoted PMCs proliferation and migration. Knockdown of ANGPTL4 can inhibit mesothelial-mesenchymal transition by suppressed glycolysis-associated gene, such as PGM1, GPI, PGK1, LDHA, ALDOA, ENO1 and TPI1. Our research established a glycolysis-associated gene signature that holds potential to assist clinicians in the personalized management of IPF. Furthermore, we identified that ANGPTL4 mediates mesothelial-mesenchymal transition, suggesting its viability as a therapeutic target for IPF treatment.